In the second quarter of 2017, biopharma companies brought in a total of $13.4 billion in financing, nearly doubling the first quarter's $6.8 billion aggregate. Initial public offerings boasted the highest dollar value, reaching $4.7 billion, or over one-third of the total. Interestingly, this financing type had one of the lowest volume counts – 18 – during the quarter, indicating the average IPO transaction was quite high. (See Exhibit 1.)
Biopharma Quarterly Deal-Making Statistics, Q2 2017
A look at financing, M&A and alliance activity April–June 2017
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.

More from Deal-Making
More from In Vivo
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.